Clinical Trial Update: Nal-IRI(Nanoliposomal Irinotecan) Plus 5-FU/LV in Metastatic Biliary Tract Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial of nal-IRI plus 5-FU/LV in metastatic biliary tract cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Biliary Tract Cancer

Drugs mentioned

• 5-FU (5-fluorouracil)
• LV (leucovorin)
• Nal-IRI (nanoliposomal irinotecan)

Snippet

Sponsor: Changhoon Yoo | Conditions: Metastatic Biliary Tract Cancer | Phase 2 | Status: COMPLETED